Polycythemia Market to Grow with a CAGR of 5.73% through 2030

Rising advancements in medical technology and a growing preventive healthcare are expected to drive the Global Polycythemia Market growth in the forecast period, 2026-2030.

According to TechSci Research report, “Polycythemia Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030”, the Global Polycythemia Market stood at USD 1.89 billion in 2024 and is anticipated to grow with a CAGR of 5.73% in the forecast period through 2030. One of the primary drivers fueling the growth of the global polycythemia market is the increasing awareness of the disease among both healthcare professionals and the general public. Advances in medical knowledge and diagnostic techniques have enabled earlier and more accurate diagnosis of polycythemia cases. This heightened awareness has led to a growing number of patients seeking medical attention and receiving appropriate treatment, consequently expanding the market. Patients and healthcare providers are now better equipped to recognize the symptoms and risk factors associated with polycythemia, such as fatigue, headache, and elevated hematocrit levels. This increased awareness has led to a surge in diagnostic tests, such as complete blood counts and genetic screenings, contributing to the overall market growth. The global population is aging, with a larger proportion of individuals over the age of 60. Polycythemia is more commonly diagnosed in older individuals, and the aging demographic has led to a rise in the prevalence of this condition. As people grow older, they are more susceptible to hematological disorders like polycythemia, which has significantly boosted the demand for diagnostic tests and treatments within the market.

Moreover, lifestyle factors such as smoking, sedentary lifestyles, and poor dietary choices have been associated with an increased risk of developing polycythemia. These factors are prevalent in many parts of the world, further contributing to the rise in polycythemia cases and the market's expansion. Pharmaceutical companies and research institutions are increasingly investing in research and development activities focused on polycythemia. This has led to a growing pipeline of potential therapies and treatment options for polycythemia patients. Traditionally, therapeutic phlebotomy has been the primary method of managing polycythemia, but innovative therapies are being developed to address the underlying genetic mutations responsible for the disorder. Targeted therapies that aim to improve patient outcomes and reduce the risk of complications are at the forefront of these efforts. Precision medicines are being designed to specifically target the molecular mechanisms driving polycythemia, offering the promise of more effective and personalized treatment regimens.

Collaborations and partnerships between pharmaceutical companies, academic research institutions, and healthcare organizations have played a pivotal role in advancing our understanding of polycythemia and developing novel treatments. These alliances have facilitated the sharing of knowledge, resources, and expertise, accelerating the pace of research and development in the field. Through collaborative efforts, researchers have gained insights into the genetic and molecular basis of polycythemia, allowing for the identification of potential drug targets. Such partnerships have also streamlined clinical trial processes and increased access to patient populations, expediting the development of new therapies.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Polycythemia Market.”

The Global Polycythemia Market is segmented into Treatment, Type, Route of Administration, Distribution Channel , Regional Distribution, and Company.

Based on Type, The primary polycythemia segment is expected to experience the fastest growth in the polycythemia market. This growth is driven by an increasing prevalence of polycythemia vera (PV), a type of primary polycythemia, along with advancements in diagnostic techniques and therapeutic developments. The rising awareness and early detection of PV have led to higher treatment rates, further propelling market expansion. Moreover, ongoing clinical trials and new drug approvals are enhancing treatment options for primary polycythemia. For instance, in March 2025, Takeda and Protagonist Therapeutics announced positive Phase III results for rusfertide, a novel hepcidin mimetic peptide therapeutic for PV. Additionally, the U.S. FDA granted orphan drug designation to VGT-1849A, a selective JAK2 inhibitor, in December 2024, further expanding treatment options. With increased R&D efforts, rising disease awareness, and therapeutic advancements, the primary polycythemia segment is poised for significant growth in the polycythemia market over the forecast period.

Based on Region, The Asia-Pacific region is expected to exhibit the fastest growth in the polycythemia market, driven by rising disease awareness, improving healthcare infrastructure, and increasing investments in research and development. The region's expanding geriatric population and growing prevalence of hematologic disorders, including polycythemia vera (PV), are key factors contributing to market growth. Governments and healthcare organizations across China, India, Japan, and South Korea are enhancing diagnostic capabilities and expanding access to advanced treatments, leading to earlier disease detection and better patient outcomes. Additionally, ongoing clinical trials and drug development initiatives by pharmaceutical companies are boosting treatment options in the region. The rising demand for innovative therapies, coupled with increasing healthcare expenditure and supportive regulatory policies, is expected to drive the Asia-Pacific polycythemia market at a rapid pace, making it the fastest-growing regional market during the forecast period.

Major companies operating in Global Polycythemia Market are:

• Novartis AG
• Incyte Corporation
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• PharmaEssentia Corporation
• Dr. Reddy's Laboratories Ltd.
• LC Laboratories
• Par Pharmaceutical
• TAJ LIFE SCIENCES PVT. LTD
• GSK plc

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Global Polycythemia Market is poised for substantial growth in the coming years, driven by several pivotal factors. Firstly, increasing disease awareness and improved diagnostic techniques are expected to lead to earlier detection of polycythemia cases. This, in turn, will likely drive the demand for treatments, fostering market expansion. Moreover, the aging global population is contributing to the rising incidence of polycythemia, as this hematological disorder is more prevalent among older individuals. As the demographic pyramid continues to shift, the market for polycythemia treatments is likely to grow, as elderly individuals are more prone to this condition. Besides, lifestyle factors such as smoking, and obesity are associated with an increased risk of polycythemia. With changing lifestyles and rising obesity rates in many regions, there is a greater likelihood of more individuals developing polycythemia, further stimulating market growth.” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Polycythemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Primary Polycythemia, Secondary Polycythemia, Pseudopolycythemia), By Treatment (Phlebotomy, Aspirin, Myelosuppressive Agents, Selective Serotonin Reuptake Inhibitor, Others), By Route of Administration (Oral, Intravenous, Intramuscular), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies),  By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global Polycythemia Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Polycythemia Market.

Contact

TechSci Research LLC

708 Third Avenue,

Manhattan, NY,

New York  10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com